CURE ETF — Direxion Daily Healthcare Bull 3X Shares

Direxion Daily Healthcare Bull 3X Shares (CURE)

Updated October 16, 2026.

CURE is an ETF. its distribution rate is 0.85%, its trailing-12-month yield is 0.86%, its expense ratio is 0.94%. Dividend Vision Distribution Safety Score™ is 61/100 (Generally safe). Total return is 3230.0% over the past 15.3 years, 2541.8 points ahead of SPY at 688.2%.

Direxion Daily Healthcare Bull 3X Shares is an ETF that seeks to deliver three times the daily performance of the healthcare sector, which encompasses pharmaceuticals, biotechnology, medical equipment and supplies, healthcare providers, life sciences tools, and healthcare technology companies. The fund carries a modest current distribution rate and distributes quarterly, with an expense ratio of 0.94%; as a leveraged product designed for short-term trading, it is not suitable for buy-and-hold investing. This ETF appeals to active traders seeking amplified exposure to healthcare sector movements on an intraday basis, not to long-term income investors.

CURE performance versus SPY

Price and return data through 2026-10-16.

Total return is 3230.0% over the past 15.3 years, 2541.8 points ahead of SPY at 688.2%. Over the past year its total return — price change plus distributions reinvested — is 68.9%. Its deepest 1-year drawdown was 31.1%.

CURE key facts

Distribution Safety Score™

61 · Generally safe

Safety-Adjusted Yield

0.52%

Issuer

Direxion

Asset type

ETF

Asset class

Equity

Inception date

06/15/2011

Expense ratio

0.94%

Distribution rate

0.85%

Distribution frequency

Quarterly

Trailing yield

0.86%

Last close

$147.76 (as of 2026-10-16)

AUM

$174,807,219

Average volume

74300.0

Dividend

$0.315

Ex-dividend date

09/22/2026

Payment date

09/29/2026

Beta

1.27

How Dividend Vision calculates yield and returns

Distribution rate (0.85%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (0.86%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Direxion; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CURE risks and drawbacks

CURE's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are quarterly, so cash flow is lumpy versus a monthly fund. The deepest 1-year drawdown on record here is 31.1%.

Who may consider CURE — and who may not

It is a weaker fit for investors who need monthly cash flow (CURE pays quarterly); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

More on CURE

• All tickers starting with C

Tagged: Leverage.

Frequently asked questions

More securities from Direxion.